Curcumin-ER prolonged subcutaneous delivery for the treatment of non-small cell lung cancer

Journal of Biomedical Nanotechnology

Volumn 12, Issue 4, 2016, Pages 679-688

  Ranjan, Amalendu P ^a   Mukerjee, Anindita ^a   Gdowski, Andrew ^a   Helson, Lawrence ^b   Bouchard, Annie ^c   Majeed, Muhammed ^d   Vishwanatha, Jamboor K ^a  

^a UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^b SignPath Pharma Inc   (United States)

^c IPS Therapeutique Inc   (Canada)

^d SABINSA CORPORATION   (United States)

Author keywords

A 549; Curcumin; Curcumin ER; Lipid Polymer Nanoparticle; Non Small Cell Lung Cancer

Indexed keywords

BIOCHEMISTRY; BIOLOGICAL MATERIALS; BIOLOGICAL ORGANS; CELLS; CYTOLOGY; DIAGNOSIS; DRUG PRODUCTS; ENZYME INHIBITION; TUMORS;

ANTI-CANCER AGENTS; CURCUMIN; FORMULATION PROCESS; IMMUNOHISTOCHEMISTRY; NON SMALL CELL LUNG CANCER; POLYMER NANOPARTICLES; SUBCUTANEOUS ROUTE; THERAPEUTIC EFFICACY;

DISEASES;

ANTINEOPLASTIC AGENT; CURCUMIN; CURCUMIN ER; KI 67 ANTIGEN; LIPOCORTIN 2; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; DELAYED RELEASE FORMULATION; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; IC50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NANOENCAPSULATION; NON SMALL CELL LUNG CANCER; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; SURFACE CHARGE; TUMOR VOLUME; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; ANIMAL; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; HUMAN; NUDE MOUSE; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; CURCUMIN; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LIPOSOMES; MICE, NUDE; TISSUE DISTRIBUTION;

EID: 84961700389     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2016.2207     Document Type: Article

References (27)

1. K. Raparia, C. Villa, M. M. Decamp, J. D. Patel, and M. P. Mehta, Molecular profiling in non-small cell lung cancer: A step toward personalized medicine. Arch. Pathol. Lab. Med. 137, 481 (2013).
2. H. Wakelee and C. P. Belani, Optimizing first-line treatment options for patients with advanced NSCLC. Oncologist. 10, 1 (2005).
3. S. Fleming, F. Lucas, and M. A. Schofield, Therapeutic area review of oncology products and players. Expert Opin. Emerg. Drugs 6, 317 (2001).
4. J. Y. Douillard, J. Eckardt, and G. V. Scagliotti, Challenging the platinum combinations in the chemotherapy of NSCLC. Lung Can. 38, 21 (2002).
5. P. M. Green, S. Guerrier-Adams, P. O. Okunji, D. Schiavone, and J. E. Smith, African American health disparities in lung cancer. Clin. J. Oncol. Nurs. 17, 180 (2013).
6. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751 (2007).
7. V. P. Torchilin, Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145 (2005).
8. N. Maurer, D. B. Fenske, and P. R. Cullis, Developments in lipo-somal drug delivery systems. Expert Opin. Biol. Ther. 1, 923 (2001).
9. L. Zhang, J. M. Chan, F. X. Gu, J.-W. Rhee, A. Z. Wang, A. F. Radovic-Moreno, F. Alexis, R. Langer, and O. C. Farokhzad, Self-assembled lipid-polymer hybrid nanoparticles: A robust drug delivery platform. ACS Nano. 2, 1696 (2008).
10. K. Hadinoto, A. Sundaresan, and W. S. Cheow, Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review. European J. Pharma. Biophar. 85, 427 (2013).
11. G. Bar-Sela, R. Epelbaum, and M. Schaffer, Curcumin as an anti-cancer agent: Review of the gap between basic and clinical applications. Curr. Med. Chem. 17, 190 (2010).
12. M. M. Yallapu, M. Jaggi, and S. C. Chauhan, Curcumin nanofor-mulations: A future nanomedicine for cancer. Drug Discov. Today. 17, 71 (2012).
13. O. Naksuriyaa, S. Okonogia, R. M. Schiffelers, and W. E. Hennink, Curcumin nanoformulations: A review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomat. 35, 3365 (2014).
14. A. Mukerjee and J. K. Vishwanatha, Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer. Res. 29, 3867 (2009).
15. R. A. Sharma, S. A. Euden, S. L. Platton, D. N. Cooke, A. Shafayat, H. R. Hewitt, T. H. Marczylo, B. Morgan, D. Hemingway, S. M. Plummer, M. Pirmohamed, A. J. Gescher, and W. P. Steward, Phase I clinical trial of oral curcumin: Biomarkers of systemic activity and compliance. Clin. Cancer Res. 10, 6847 (2004).
16. A. L. Cheng, C. H. Hsu, J. K. Lin, M. M. Hsu, Y. F. Ho, T. S. Shen, J. Y. Ko, J. T. Lin, B. R. Lin, W. Ming-Shiang, H. S. Yu, S. H. Jee, G. S. Chen, T. M. Chen, C. A. Chen, M. K. Lai, Y. S. Pu, M. H. Pan, Y. J. Wang, C. C. Tsai, and C. Y. Hsieh, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21, 2895 (2001).
17. N. Dhillon, B. B. Aggarwal, R. A. Newman, R. A. Wolff, A. B. Kunnumakkara, J. L. Abbruzzese, C. S. Ng, V. Badmaev, and R. Kurzrock, Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491 (2008).
18. P. Anand, A. B. Kunnumakkara, R. A. Newman, and B. B. Aggarwal, Bioavailability of curcumin: Problems and promises. Mol. Pharmaceutics 4, 807 (2007).
19. R. T. Mehta, R. L. Hopfer, L. A. Gunner, R. L. Juliano, and G. Lopez-Berestein, Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis. Antimicrob Agents Chemother. 31, 1897 (1987).
20. J. Hao, X. Fang, Y. Zhou, J. Wang, F. Guo, F. Li, and X. Peng, Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int. J. Nanomed. 6, 683 (2011).
21. A. P. Ranjan, A. Mukerjee, L. Helson, and J. K. Vishwanatha, Scale up, optimization and stability analysis of curcumin C3 complex-loaded nanoparticles for cancer therapy. J. Nanobiotech. 10, 38 (2012).
22. G. Radhakrishna Pillai, A. S. Srivastava, T. I. Hassanein, D. P. Chauhan, and E. Carrier, Induction of apoptosis in human lung cancer cells by curcumin. Cancer Lett. 208, 163 (2004).
23. J. Li, Y. Jiang, J. Wen, G. Fan, Y. Wu, and C. Zhang, A rapid and simple HPLC method for the determination of curcumin in rat plasma: Assay development, validation and application to a pharmacokinetic study of curcumin liposome. Biomed. Chromatogr. 23, 1201 (2009).
24. D. Wang, M. S. Veena, K. Stevenson, C. Tang, B. Ho, J. D. Suh, V. M. Duarte, K. F. Faull, K. Mehta, E. S. Srivatsan, and M. B. Wang, Liposome encapsulated curcumin suppresses growth of HNSCC in vitro and in xenografts through the inhibition of NFKB by an AKT independent pathway. Clin. Cancer Res. 14, 6228 (2008).
25. I. Jutooru, G. Chadalapaka, P. Lei, and S. Safe, Inhibition of NFKB and pancreatic cancer cell and tumor growth by curcumin is dependent on specificity protein down-regulation. J. Biol. Chem. 285, 25332 (2010).
26. M. Valapala, S. I. Thamake, and J. K. Vishwanatha, A competitive hexapeptide inhibitor of annexin A2 prevents hypoxia-induced angiogenic events. J. Cell Sci. 124, 1453 (2011).
27. A. Mukerjee, J. Shankardas, A. P. Ranjan, and J. K. Vishwanatha, Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells. Nanotech. 22, 445101 (2011).